Skip to main content

Table 1 Studies of approved PD-1 inhibitors for advanced or metastatic gastric and GEJ cancers (FDA or Japan)

From: Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort

Trial ATTRACTION-2 KEYNOTE-062
Arm 1
KEYNOTE-059
Cohort 1
CT01876511
Cohort C
PD-1 inhibitor Nivolumab Pembrolizumab Pembrolizumab Pembrolizumab
Treatment line 3rd or later 1st 3rd or later 2nd or later
Phase III III II II
Allocation Randomized, double-blind Randomized Single arm Single arm
PD-L1 status not assessed positive positive/negative not assessed
MS status not assessed not assessed not assessed MSI
Sample size Nivolumab: 330 (total: 493) 254 259 47
ECOG PS 0–1 0–1 0–1 0–1
% Asian 100% 27% < 23% 4.3%
ORR 11.2% 15% 11.6% 47%
Median OS (months) 5.3 10.6 5.6 not reached
Reference [11] [18] [14] [19]